Shanghai Upper Bio-tech Co., Ltd. is located in Zhangjiang Science City Modern Medical Device Park in Shanghai. Our company specializes in the development, production, sales, and big data services of internet-enabled intelligent point-of-care testing (iPOCT) products. Upper holds over 400 intellectual property rights and has participated in more than 20 national and provincial-level major projects. It has led the publication of three industry monographs, including POCT, iPOCT, and IVD +(Big Data Smart Diagnosis). Our company has received seven scientific and technological awards, 10+ honors such as National Key New Products and Shanghai High-Tech Achievement Transformation Projects, and contributed to five national, industrial, and group standards. Designated as a National Specialized and Sophisticated Small Giant Enterprise, a National Intellectual Property Demonstration Enterprise, and home to a Postdoctoral Research Workstation, Shanghai Engineering Technology Research Center for Point-of-Care Testing, and Shanghai Enterprise Technology Center, Upper is a leader in innovation. Focused on rapid quantitative testing for cardiovascular diseases, diabetes nephropathy, autoimmune disorders, reproductive health, infectious diseases, and inflammatory infections, Our company has launched over 60 instrument and reagent products. These are used in over 1,000 medical institutions nationwide and internationally, serving tens of millions of patients annually. Through publications and industry initiatives, Our company introduced the "iPOCT" concept centered on precision, automation, cloud-based services, and sharing, along with a "smart diagnosis + health big data" model. It also pioneered the "3D Innovation(Instrument + Reagent + AI)" strategy integrating instruments, reagents, and cloud quality control. Listed on the National Equities Exchange and Quotations (NEEQ) under the code 873758 and entering the Innovation Tier, Upper leverages Shanghai Free Trade Zone policies and Zhangjiang’s biopharmaceutical ecosystem. The company aims to accelerate synergies between capital, technology, and markets, establishing itself as a premier brand in China’s digital diagnostic sector while contributing to Shanghai’s and China’s strategic goals.
公司简介 上海奥普生物医药股份有限公司地处上海张江科学城现代医疗器械园,是一家专注互联网+医学智慧即时检测(iPOCT)产品开发、生产、销售及大数据服务的高新技术企业。 公司创新数智高端医疗器械承担或参与国家、省部级等重大专项20余项,申请各类知识产权400余项,牵头编写并出版行业专著3部,获科学技术奖7项,国家重点新产品、上海市重点新产品、高新技术成果转化项目等10余项,参与建立国家、行业和团体标准等5项,是国家级专精特新“小巨人”企业、国家知识产权示范企业,并建有企业博士后科研工作站、上海即时检测医学工程技术研究中心、上海市企业技术中心等。 定位于心脑血管疾病、糖尿病肾病、自身免疫系统、优生优育、传染病以及炎症感染疾病等快速定量检测领域,公司先后推出60余个仪器和试剂品种,在全国及海外逾千家医疗机构得到应用,每年服务患者数千万人次。 公司在国内陆续出版了《即时检验》、《智慧即时检测&iPOCT》 及《IVD+ 大数据智慧诊断》叁本行业学术专著,提出了以“精准化、自动化、云端化、共享化”为核心的“iPOCT”理念以及“智慧诊断+健康大数据”的模式;并推动了POCT国家标准的出台。在对未来发展趋势的精准预测下,公司率先提出了仪器、试剂、云质控为一体的“3D创新”理念并付诸实施。 目前公司已在新三板挂牌并进入创新层(证券简称:奥普生物,证券代码:873758),依托上海自贸区的政策开放与制度创新,借助全球科创中心张江生物医药产业的聚集优势,未来,公司将会进一步加强自主创新,加快“资本+技术+市场” 的高度融合发展,打造成为中国医学数智诊断企业一流品牌,为服务上海战略与国家战略作出贡献。
- Our objective is to showcase and promote the Armada-500 Integrated Biochemistry & Immunoassay Analyzer and the ExoFaster-600 Fully Automated Exosome Extraction Platform in Southeast Asia, enhance brand and product awareness, connect with healthcare institutions, research organizations, laboratories, and distributors, and facilitate product sales, evaluations, and distribution partnerships.
- We are looking for national general agents or regional agents in Southeast Asia with industry resources, sales channels and local service capability to jointly drive market access, promotion and sales of the Armada-500 and ExoFaster-600, and to build long-term, stable partnerships.我们正在东南亚市场寻找具备行业资源、销售渠道及本地服务能力的国家级总代理或区域代理商,共同推动 Armada-500 和 ExoFaster-600 的市场准入、推广与销售,建立长期稳定的合作伙伴关系。
- No否
- CE